REGISTERED
on 04 Apr 2023
Last Applicant/ Owned by
3545 Cray Court
San Diego
CA
92121
Serial Number
97541695 filed on 09th Aug 2022
Registration Number
7020760 registered on 04th Apr 2023
Correspondent Address
Marilyn F. Kelly
Marilyn F. Kelly Bristol-Myers Squibb Company
Trademark Dept., Mailstop D.4243
Princeton, NJ 08648-4000
United States
Filing Basis
1. intent to use
2. use application currently
Disclaimer
NO DATA
KRAZATI
research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals
Classification Information
Class [042]
Computer & Software Services & Scientific Services
research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals
First Use Date in General
13th Dec 2022
First Use Date in Commerce
13th Dec 2022
Mark Details
Serial Number
No 97541695
Mark Type
No Service Mark
Attorney Docket Number
No 00163765-US
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 25th Jun 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| 25th Jun 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 25th Jun 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| 04th Apr 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 04th Apr 2023 | REGISTERED-PRINCIPAL REGISTER |
| 02th Mar 2023 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| 01st Mar 2023 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| 30th Jan 2023 | STATEMENT OF USE PROCESSING COMPLETE |
| 30th Jan 2023 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 30th Dec 2022 | USE AMENDMENT FILED |